SC 13G/A - Chain Bridge I (0001845149) (Subject)

SC 13G/A - Chain Bridge I (0001845149) (Subject)

SC 13G/A - Chain Bridge I (0001845149) (Subject)

SC 13G - Chain Bridge I (0001845149) (Subject)

SC 13G/A - Chain Bridge I (0001845149) (Subject)

SC 13G/A - Chain Bridge I (0001845149) (Subject)

SC 13G/A - Chain Bridge I (0001845149) (Subject)

SC 13G - Chain Bridge I (0001845149) (Subject)

SC 13G - Chain Bridge I (0001845149) (Subject)

SC 13G - Chain Bridge I (0001845149) (Subject)

NEW YORK and SANTA BARBARA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company's strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. The global cannabis pharmaceuticals market size was estimated at USD 3.4 billion in 2023 and is anticipated to grow at a CAGR of 53.3% from 2024 to 2030. The investor deck is now available on

Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP)The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal closeThe business combination is expected to be completed in the fourth quarter of 2024, with the combined company to be listed on Nasdaq Capital Markets under the ticker "PHYX" NEW YORK and SANTA BARBARA, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Phytani

Chain Bridge I (the "Company") (NASDAQ:CBRGU, CBRG, CBRGW))), a special purpose acquisition company, today announced that it will redeem all of its outstanding Class A ordinary shares, par value $0.0001 (the "Public Shares"), effective as of the close of business on November 15, 2023, as the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the "Articles"). The Company concluded it would be unable to meet its expectations for quality and long-term return potential by completing an initial business combination by November 15, 2023 (twenty-four months from the closing of the Company

Chain Bridge I (NASDAQ:CBRG) announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction, valued at $58 million, also includes the assumption of preferred stock and short-term debt, which will convert to preferred stock upon the deal’s closure, slated for the fourth quarter of 2024. Phytanix Bio’s Strategic Acquisition Overview Phytanix Bio, a company founded by former GW Pharmaceuticals leaders, holds exclusive intellectual property that has been central to the creation of FDA-approved cannabinoid-based medicines like Sativex and Epidiolex. With the ac

Upon closing of the transaction, expected to occur in the fourth quarter of 2024, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "PHYX." Phytanix is pioneering a new and innovative approach in the development of cannabinoid and cannabinoid-like medicines. The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close

Individuals can visit corebridgedirect.com or call 800-294-4544 for a free life insurance quote and evaluation of their coverage needsCorebridge Financial, Inc. (NYSE:CRBG) today announced the name change of its long-standing direct-to-consumer life insurance business from AIG Direct to Corebridge Direct.

- SEC Filing

Chain Bridge I (the "Company") (NASDAQ:CBRGU, CBRG, CBRGW))))), a special purpose acquisition company, today announced that it will redeem all of its outstanding Class A ordinary shares, par value $0.0001 (the "Public Shares"), effective as of the close of business on November 15, 2023, as the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the "Articles").The Company concluded it would be unable to meet its expectations for quality and long-term return potential by completing an initial business combination by November 15, 2023 (twenty-four months from the closing of the Company's